166 related articles for article (PubMed ID: 37611121)
21. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
22. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract][Full Text] [Related]
23. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
24. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
25. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
26. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
27. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
28. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
29. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
30. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
31. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
32. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
33. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
34. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
35. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
[TBL] [Abstract][Full Text] [Related]
37. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
38. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Justeau G; Huchot E; Simonneau Y; Roa M; Le Treut J; Le Garff G; Bylicki O; Schott R; Bravard AS; Tiercin M; Lamy R; De Chabot G; Marty A; Moreau D; Locher C; Bernier C; Chouaid C; Descourt R
Lung Cancer; 2022 Dec; 174():45-49. PubMed ID: 36323057
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.
Gray JE; Hsu H; Younan D; Suri G; Chia V; Spira A; Johnson M
Lung Cancer; 2023 Jul; 181():107260. PubMed ID: 37285629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
